Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Ist das der Durchbruch für den KI-Biotech-Geheimtipp?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3D9NV | ISIN: DK0062266474 | Ticker-Symbol: PI3
Tradegate
04.04.25
11:01 Uhr
52,80 Euro
-3,00
-5,38 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
GUBRA A/S Chart 1 Jahr
5-Tage-Chart
GUBRA A/S 5-Tage-Chart
RealtimeGeldBriefZeit
52,2052,4011:05
52,2052,6011:05
ACCESS Newswire
163 Leser
Artikel bewerten:
(1)

Gubra Welcomes New Board Members at 2025 AGM

Finanznachrichten News

HØRSHOLM, DK / ACCESS Newswire / April 3, 2025 / Gubra (CPH:GUBRA)

Following Gubra's Annual General Meeting 2025 taking place earlier today we are pleased to confirm some exciting changes to the Board welcoming new perspectives to support the journey ahead.

As recommended by the Nomination Committee, the following members were re-elected to the Board:

  • Jacob Jelsing

  • Monika Lessl

  • Alexander Thomas Martensen-Larsen

  • Astrid Haug

  • Arndt Justus Georg Schottelius

Henriette Dræbye Rosenquist did not stand for re-election. The Board extends heartfelt thanks to Henriette for her significant contributions wishing her all the best in her new endeavours.

Welcoming new and old faces
The Board welcomes Gubra Co-Founder and Scientific Advisor Niels Vrang's re-entry to the board and Claudia Mitchell as new members of the Board. Their collective experience in biotech innovation, research, and entrepreneurship will be a valuable asset to the next chapters in the company's growth journey.

A new Chair at the helm
Monika Lessl, previously serving as a Board member, has been appointed as the new Chair, succeeding Jacob Jelsing, who remains an active member of the Board. As internationally experienced pharma and life science executive with more than 25 years of R&D and Innovation leadership, Monika brings visionary leadership and deep insight into innovation and sustainability - two key pillars of Gubra's mission.

Quote from incoming Chair, Monika Lessl:

"I am honoured and excited to take over the chair at Gubra and look forward to supporting Gubra's impressive growth journey and taking it to the next level. The strength of the people at Gubra, the deep commitment to science, and the technological capabilities are truly exceptional. This will remain the foundation as well as the commitment to society by contributing to a healthy planet."

With a refreshed Board and continued commitment to scientific excellence and sustainability, Gubra is well-positioned for the next chapter in its growth journey.

Learn more about the AGM agenda and get to know the Board of Directors through their CVs here: Notice to convene Annual General Meeting 2025

Contacts at Gubra
Media: Sofia Pitt Boserup, sbo@gubra.dk, +45 4188 9586
Investors: Kristian Borbos, kbo@gubra.dk, +45 3080 8035

About Gubra
Gubra, founded in 2008 in Denmark, listed on Nasdaq Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas - CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. Gubra has approx. 260 employees and in 2024 revenue of DKK 266 million. See www.gubra.dk for more information.

Attachments
Gubra Welcomes New Board Members at 2025 AGM

SOURCE: Gubra



View the original press release on ACCESS Newswire

© 2025 ACCESS Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.